Inogen Inc. (INGN) EVP Sells $159,500.00 in Stock
Inogen Inc. (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $63.80, for a total value of $159,500.00. Following the sale, the executive vice president now owns 4,833 shares in the company, valued at approximately $308,345.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Matt Scribner also recently made the following trade(s):
- On Wednesday, October 12th, Matt Scribner sold 4,551 shares of Inogen stock. The stock was sold at an average price of $59.45, for a total value of $270,556.95.
- On Monday, September 19th, Matt Scribner sold 4,551 shares of Inogen stock. The stock was sold at an average price of $60.18, for a total value of $273,879.18.
- On Thursday, August 18th, Matt Scribner sold 2,320 shares of Inogen stock. The stock was sold at an average price of $56.39, for a total value of $130,824.80.
Inogen Inc. (NASDAQ:INGN) opened at 66.74 on Monday. Inogen Inc. has a 52 week low of $28.81 and a 52 week high of $67.78. The firm has a market capitalization of $1.35 billion, a P/E ratio of 94.00 and a beta of 0.99. The stock has a 50 day moving average price of $58.64 and a 200-day moving average price of $53.98.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, November 3rd. The medical technology company reported $0.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.03. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The business had revenue of $54.42 million for the quarter, compared to the consensus estimate of $47.89 million. During the same quarter last year, the business posted $0.13 earnings per share. The company’s revenue for the quarter was up 33.5% on a year-over-year basis. Analysts anticipate that Inogen Inc. will post $0.62 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in INGN. Price T Rowe Associates Inc. MD increased its stake in Inogen by 13.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 271,740 shares of the medical technology company’s stock worth $16,277,000 after buying an additional 32,400 shares during the last quarter. LPL Financial LLC purchased a new stake in Inogen during the third quarter worth $658,000. Bamco Inc. NY increased its stake in Inogen by 33.3% in the third quarter. Bamco Inc. NY now owns 16,000 shares of the medical technology company’s stock worth $958,000 after buying an additional 4,000 shares during the last quarter. Gerstein Fisher purchased a new stake in Inogen during the third quarter worth $227,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Inogen during the third quarter worth $670,000.
A number of equities research analysts recently weighed in on INGN shares. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research report on Tuesday, October 4th. Stifel Nicolaus downgraded Inogen from a “buy” rating to a “hold” rating in a report on Friday, August 5th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their target price on Inogen from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, August 5th. Finally, Needham & Company LLC lifted their target price on Inogen from $64.00 to $66.00 and gave the stock a “strong-buy” rating in a report on Friday, November 4th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Inogen currently has a consensus rating of “Buy” and a consensus price target of $58.83.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Stock Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related stocks with our FREE daily email newsletter.